Departamento de Microbiologia, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brasil.
Mem Inst Oswaldo Cruz. 2010 Aug;105(5):687-91. doi: 10.1590/s0074-02762010000500015.
The potential use of the Trypanosoma cruzi metacyclic trypomastigote (MT) stage-specific molecule glycoprotein-82 (gp82) as a vaccine target has not been fully explored. We show that the opsonization of T. cruzi MT with gp82-specific antibody prior to mucosal challenge significantly reduces parasite infectivity. In addition, we investigated the immune responses as well as the systemic and mucosal protective immunity induced by intranasal CpG-adjuvanted gp82 vaccination. Spleen cells from mice immunized with CpG-gp82 proliferated and secreted IFN-γ in a dose-dependent manner in response to in vitro stimulation with gp82 and parasite lysate. More importantly, these CpG-gp82-immunized mice were significantly protected from a biologically relevant oral parasite challenge.
尚未充分探索克氏锥虫（Trypanosoma cruzi）循环型无鞭毛体（MT）阶段特异性分子糖蛋白 82（gp82）作为疫苗靶标的潜在用途。我们表明，在粘膜攻击前用 gp82 特异性抗体调理克氏锥虫 MT，可显著降低寄生虫感染性。此外，我们还研究了鼻腔 CpG 佐剂 gp82 接种诱导的免疫反应以及全身和粘膜保护性免疫。用 CpG-gp82 免疫的小鼠的脾细胞在体外用 gp82 和寄生虫裂解物刺激时，以剂量依赖性方式增殖并分泌 IFN-γ。更重要的是，这些 CpG-gp82 免疫的小鼠从生物学相关的口服寄生虫攻击中受到显著保护。
